Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial -

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
Information type: Randomised controlled trials
Source: The Lancet Diabetes & Endocrinology
Specialities: Diabetes
Summary
RCT (n=504) found that at week 52 the odds of achieving an HbA1c < 7% was significantly better with flexible dose adjustments of oral semaglutide (3, 7, or 14 mg per day) than sitagliptin (OR, 4.40, 95% CI 2.89–6.70, p<0.0001).
UKMi comment
The authors of a related commentary note that flexible dose adjustment did not decrease the prevalence of study drug discontinuations due to adverse events compared with that observed in other oral semaglutide studies.
Related links: Comment